Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Immunotherapy for Renal Cell Carcinoma Approved as Advanced Therapy
August 30, 2010
- R-Tech Ueno Applies for Arbitration in Disputes with Takeda over Agreement on Amitiza
August 30, 2010
- Eli Lilly Discontinues Development of Semagacestat for AD
August 30, 2010
- Cervarix Adverse Events Reported from 37 Recipients
August 30, 2010
- Alfresa to Make Tampei Nakata Wholly-Owned Subsidiary
August 30, 2010
- IPSN, INCJ to Invest in IP Rights in 4 Fields
August 30, 2010
- JCQHC Calls For a Rest for MTX
August 30, 2010
- PI Forum to Promote Drug Discovery: Chairman Asano
August 30, 2010
- Mebix's EDC Receives CDISC Certification
August 30, 2010
- Industry-Funded Trials More Likely to Publish Favorable Results: US Study
August 30, 2010
- JMA Expresses Concern about Commercial Use of Social Security Numbering System
August 30, 2010
- DSP Screens Candidates for Lurasidone's Successors
August 30, 2010
- Korosho to Help Drug Industry Become Japan's Leading Industry: Mr Asonuma
August 30, 2010
- AnGes MG to Undertake Joint Research on siRNA with alphaGEN
August 30, 2010
- Korosho to Create 10 Million-Person DB on ADR: Mr Nagatsuma
August 30, 2010
- Nesina Jumps to No. 1 Place in GP Market: Rep Track Survey
August 30, 2010
- Korosho to Allow Reimbursement of Drugs Applied Based on Data from Public Domain
August 30, 2010
- Toxicity Study Completed for LTT Bio-Pharma's Inhalant PC-SOD
August 30, 2010
- Non-specialists Should Rely on New Anti-Epileptic Drugs: Prof. Nakasato
August 30, 2010
- Wholesalers' Gross Profit Rate below 7% for the First Time
August 30, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…